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Introduction: The advent of anti-tumor necrosis factor alpha (anti-TNFα) drugs has considerably improved medical
management in rheumatoid arthritis (RA) patients, although it has been reported to be ineffective in a fraction of them.
MicroRNAs (miRNAs) are small, non-coding RNAs that act as fine-tuning regulators of gene expression. Targeting
miRNAs by gain or loss of function approaches have brought therapeutic effects in various disease models. The
aim of this study was to investigate serum miRNA levels as predictive biomarkers of response to anti-TNFα therapy in
RA patients.
Methods: In total, 95 RA patients undergoing anti-TNFα/disease-modifying antirheumatic drugs (anti-TNFα/DMARDs)
combined treatments were enrolled. Serum samples were obtained at 0 and 6 months and therapeutic efficacy
was assessed. miRNAs were isolated from the serum of 10 patients before and after anti-TNFα/DMARDs combination
therapy, cDNA transcribed and pooled, and human serum miRNA polymerase chain reaction (PCR) arrays were
performed. Subsequently, selected miRNAs were analyzed in a validation cohort consisting of 85 RA patients.
Correlation studies with clinical and serological variables were also performed.
Results: Ninety percent of RA patients responded to anti-TNFα/DMARDs combination therapy according to European
League Against Rheumatism (EULAR) criteria. Array analysis showed that 91% of miRNAS were overexpressed and 9%
downregulated after therapy. Functional classification revealed a preponderance of target mRNAs involved in reduction
of cells maturation - especially on chondrocytes - as well as in immune and inflammatory response, cardiovascular
disease, connective tissue and musculoskeletal system. Six out of ten miRNAs selected for validation were found
significantly upregulated by anti-TNFα/DMARDs combination therapy (miR-16-5p, miR-23-3p, miR125b-5p, miR-126-3p,
miRN-146a-5p, miR-223-3p). Only responder patients showed an increase in those miRNAs after therapy, and paralleled
the reduction of TNFα, interleukin (IL)-6, IL-17, rheumatoid factor (RF), and C-reactive protein (CRP). Correlation studies
demonstrated associations between validated miRNAs and clinical and inflammatory parameters. Further, we identified
a specific plasma miRNA signature (miR-23 and miR-223) that may serve both as predictor and biomarker of response
to anti-TNFα/DMARDs combination therapy.
Conclusions: miRNA levels in the serum of RA patients before and after anti-TNFα/DMARDs combination therapy are
potential novel biomarkers for predicting and monitoring therapy outcome.* Correspondence: rosario.lopez.exts@juntadeandalucia.es
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Rheumatoid arthritis (RA) is a systemic, inflammatory,
autoimmune disorder of unknown etiology that affects
primarily the articular cartilage and bone. Characteris-
tic features of RA pathogenesis are persistent inflam-
mation, synovium hyperplasia and cartilage erosion
accompanied by joint swelling and joint destruction [1].
Early treatment can prevent severe disability and lead
to remarkable patient benefits, although a lack of thera-
peutic efficiency in a considerable number of patients
remains problematic.
Tumor necrosis factor alpha (TNFα) plays a central
role in the pathogenesis of RA and is instrumental in
causing joint destruction, the clinical hallmark of the
disease. It induces macrophages and other cells to se-
crete proinflammatory cytokines (that is interleukin (IL)-
1, IL-6 and IL-8), leads to T cell activation, and induces
endothelial cells to express adhesion molecules [2].
TNFα is involved in the differentiation and maturation
of osteoclasts (the main cells involved in arthritic bone
destruction), and stimulates fibroblasts, osteoclasts and
chondrocytes to release proteinases, which destroy ar-
ticular cartilage and bone [2,3].
The introduction of anti-TNF therapy has significantly
improved the outlook for patients suffering from RA.
Yet, a substantial proportion of patients fail to respond
to these therapies [4]. Treatment response is likely to be
multifactorial; however, variation in genes or their ex-
pression may identify those most likely to respond [5].
By targeted testing of variants within candidate genes,
potential predictors of anti-TNF response have been re-
ported [6]. However, very few markers have been repli-
cated consistently between studies. Other potential
serum biomarkers of response have also been explored
including cytokines and autoantibodies, with antibodies
developing to the anti-TNF drugs themselves being cor-
related with treatment failure [7-9].
More recently, epigenetic anomalies are emerging as
key pathogenic features of RA. The effects of epigenetics
in RA range from contributing to complex disease
mechanisms to identifying biomarkers for early diagnosis
and response to therapy. Key epigenetic areas in RA
have been evaluated namely DNA methylation, histone
modification, and expression and/or function of micro-
RNAS [10]. MicroRNAs (miRNAs) are small, non-coding
RNAs that, depending upon base pairing to messenger
RNA (mRNA) mediate mRNA cleavage, translational
repression or mRNA destabilization. miRNAs are in-
volved in crucial cellular processes and their dysregula-
tion has been described in many cell types in different
diseases [1]. In fact, abnormalities in miRNA expression
related to inflammatory cytokines, T helper 17 (Th-17)
and regulatory T cells as well as B cells have been de-
scribed in several autoimmune diseases [11]. Over thepast several years it has become clear that alterations
exist in the expression of miRNAs in patients with RA.
Increasing number of studies have shown that dysregu-
lation of miRNAs in peripheral blood mononuclear
cells [12], isolated T lymphocytes [13], synovial tissue
and synovial fibroblasts - that are considered key effec-
tors cells in joint destruction - [14-16], contributes to
inflammation, degradation of extracellular matrix and
invasive behavior of resident cells. Moreover, altered
expression of miRNA in plasma and synovial fluid of
RA patients has been demonstrated [17].
It has been established that miRNAs can be aberrantly
expressed even in the different stages of RA progression,
allowing miRNAs to help monitor disease severity and
understand its pathogenesis [10]. Yet, to date no study
has evaluated the changes that occurred in the profile of
serum miRNAs in RA patients after anti-TNFα therapy.
Therefore, to identify possible biomarkers predictive of
the therapeutic effect of anti-TNFα drugs in RA, we in-




Ninety-five RA patients were included in the study
(during a period of 24 months) after obtaining approval
from the ethics committee of the Reina Sofia Hospital
from Cordoba (Spain). All the RA patients fulfilled the
American College of Rheumatology criteria for the clas-
sification of RA [18]. Patients provided written in-
formed consent.
All patients had inadequate response to at least two
disease-modifying antirheumatic drugs (DMARDs), one
of which was methotrexate. Patients received DMARDs
in monotherapy or in combination therapy. Only pa-
tients who were naïve to anti-TNFα agents were in-
cluded in the study. Therapy with anti-TNFα agents was
stable during the study and was associated to DMARDs
(Table S5 in Additional file 1). Within the cohort, 55 pa-
tients were given infliximab (IFX; 3 mg/kg/day intraven-
ous infusion at times 0, 2 and 6 weeks, and every 8
weeks thereafter); 25 received etanercept (ETA, 25 mg
subcutaneously twice weekly), and 15 patients were
treated with adalimumab (ADA; 40 mg subcutaneously
every week) for 6 months. Blood samples were obtained
before the start and at the end of the treatment. To
avoid blood composition changes promoted by diet
and circadian rhythms, samples were always collected
in the early hours in the morning and after a fasting
period of 8 hours.
Clinical and laboratory parameters of the RA patients
included in the treatment protocols are displayed in
Table 1. Patients were evaluated clinically and analytic-
ally at baseline (T1) and 6 months of treatment (T2).
Table 1 Clinical characteristics of rheumatoid arthritis





(n = 10) (n = 85)
Sex (male/female) 1/9 11/74
Age, mean (range) 54.6 (38-74) 53.6 (24-72)
Disease duration (y), mean (range) 10.1 (2-23) 10.4 (1-36)
Smoking, number (%) 4 (40%) 23 (27.1%)
TJC, mean 13.7 ± 5.8 15.7 ± 4.6
SJC, mean 16.9 ± 6.5 11.5 ± 3.7
DAS28, mean 5.9 ± 0.7 5.7 ± 0.6
SDAI 39.7 ± 14.9 36.3 ± 10.9
HAQ 2.14 ± 0.5 2.1 ± 0.3
ESR (mm), mean 55 ± 18.62 55.9 ± 16.6
CRP (mg/dL), mean 3.6 ± 1.12 3.8 ± 2.1
Positive rheumatoid factor, n (%) 7 (70%) 60 (70.6%)
Positive anti-CCP antibody, n (%) 4 (40%) 59 (69.4%)
Medication, n (%)
Infliximab 9 (90%) 46 (54.1%)
Etanercept 1 (10%) 24 (28.2%)
Adalimumab 0 15 (17.6%)
Corticoids, n(%) 4 (40%) 55 (64.7%)
Hydroxychloroquine, n (%) 3 (30%) 22 (25.9%)
Azathioprine, n (%) 0 (0%) 5 (5.9%)
Metotrexate, n (%) 7 (70%) 58 (68.2%)
Sulfasalazine, n (%) 1 (10%) 7 (8.2%)
Cyclosporine, n (%) 1 (10%) 2 (2.4%)
Leflunomide, n (%) 2 (20%) 33 (38.8%)
TJC, tender joint count; SJC, swollen joint count; DAS28, disease activity score;
SDAI, simplified disease activity index; HAQ, health assessment questionnaire;
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; anti-CCP,
anti-cyclic citrullinated peptide antibodies.
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tender joint count (TJC), visual analog scale of pain
(VAS; range 1 to 100 mm) of patient and clinician, sim-
ple disease activity index (SDAI), health assessment
questionnaire (HAQ) and number of DMARDs associ-
ated with anti-TNFα treatment. Serological evaluation
included analysis of rheumatoid factor (RF), anti-cyclic
citrullinated peptide antibodies (anti-CCPs), C-reactive
protein (CRP, mg/L) and erythrocyte sedimentation rate
(ESR, mm/h).
Response to anti-TNFα/DMARDs combination treat-
ment was assessed by the (European League Against
Rheumatism (EULAR) criteria, based on the 28-joint
disease activity score (DAS28). The patients were cate-
gorized into responders and non-responders based on
the change in the DAS28 score. An improvement in
DAS28 over ≥1.2 and a DAS28 value ≤3.2 after 6 monthsof treatment was considered a good response; a DAS28
value after 6 months between 3.2 and 5.1 and a reduction
between 0.6 and 1.2 was considered a moderate response.
Both of them were considered responders to the therapy.
DAS28 score at T2 > 5.1 or a reduction in DAS28 under
0.6 was considered a non-response.
Blood sample collection and assessment of biological
parameters
Whole blood from subjects was collected by direct venous
puncture either, into tubes with ethylenediaminetetraace-
tic acid (EDTA) as an anticoagulant, or into specific tubes
for obtaining serum. All the blood was processed for the
isolation of plasma or serum within 4 h of collection. The
blood was processed by spinning at 2,000 × g for 10 min
at room temperature. Then, plasma and serum were
transferred to a fresh RNase-free tube and stored at −80°C.
RF was measured by immunoturbidimetric assay (Quantia
RF kit, Abbot Laboratories, Chicago, IL, USA) and con-
centrations >30 IU/mL were considered positive. Deter-
mination of anti-CCP antibody was tested with the
EDIA™ anti-CCP kit (Euro Diagnostica, Malmö,
Sweden). Positive anti-CCP titers were considered at a
concentration of >5 U/mL.
Plasmatic levels of IL-6, IL-4, IL-17, IL-22, IL-23,
monocyte chemotactic protein (MCP-1), TNFα, soluble
TNF receptor II (sTNFRII) and vascular endothelial
growth factor (VEGF) at T1 and T2 were quantified
using cytofluorometry-based enzyme-linked immunosorb-
ent assay (ELISA) technique in accordance with manufac-
turer’s instructions using FlowCytomix kit (eBioscience,
San Diego, CA, USA). Results were calculated using the
FlowCytometry Pro software (eBioscience).
Isolation of microRNAs from serum
Total RNA, including the miRNA fraction, was extracted
from serum by using the QIAzol miRNeasy kit (Qiagen,
Valencia, CA, USA) with some modifications. A total of
200 μl of serum were thawed on ice and lysed in 1 mL
QIAzol Lysis Reagent (Qiagen). Samples in QIAzol were
incubated at room temperature for 5 min to inactivate
RNases. To adjust for variations in RNA extraction and/or
copurification of inhibitors, 5 fmol of spike-in non-human
synthetic miRNA (C. elegans miR-39 miRNA mimic:
5′-UCACCGGGUGUAAAUCAGCUUG-3′) were added
to the samples after the initial denaturation. The
remaining extraction protocol was performed according
to the manufacturer’s instruction. Total RNA was eluted
in 14 μl of RNase-free water and stored at −80°C.
MicroRNA expression profiling
To identify the changes that occurred in the expression
levels of miRNAs in serum from patients treated with
anti-TNFα/DMARDs combination therapy, a Human
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formed. This array profiles the expression of 84 miRNAs
detectable and differentially expressed in serum, plasma,
and other bodily fluids. Those miRNAs have been care-
fully selected based on published results that suggest a
correlation with serum expression levels and specific dis-
eases. A pool with 2 μl from RNA purified from 10 optimal
responder RA patients before treatment, and another pool
with 2 μl from RNA purified from the same 10 patients
after treatment was performed.
In a reverse-transcription reaction using miScript HiS-
pec Buffer from the miScript II RT kit (Qiagen), mature
miRNAs were polyadenylated by poly(A) polymerase
and subsequently converted into cDNA by reverse tran-
scriptase with oligo-dT priming. The formulation of
miScript HiSpec Buffer facilitated the selective conver-
sion of mature miRNAs into cDNA, while the conver-
sion of long RNAs, such as mRNAs was suppressed. As
a result, background signals potentially contributed by
long RNA were non-existent.
The cDNA prepared in a reverse-transcription reac-
tion was used as a template for real-time PCR analysis
using miScript miRNA PCR array (which contains
miRNA-specific miScript Primer Assays) and the miS-
cript SYBR Green kit, (which contains the miScript Uni-
versal Primer -reverse primer- and QuantiTect SYBR
Green PCR Master Mix). To profile the mature miRNA
expression, a premix of cDNA, miScript Universal Pri-
mer, QuantiTect SYBR Green PCR Master MIX, and
RNAse-free water, was added to a miScript miRNA PCR
array. That array was provided in a 96-well plate format
and included replicates of a miRNA reverse transcription
control assay (miRTC) and a positive PCR control
(PPC). Those were the quality control assays used to de-
termine the presence of reverse transcription and real-
time PCR inhibitors.
Raw data were analyzed with the data analysis software
for miScript miRNA PCR arrays. The expression levels
of miRNAs were normalized to the mean of spiked-in
miRNA Cel-miR-39 and were calculated using the 2-ΔΔCt
method.
Quantitative real-time PCR
A fixed volume of 3 μl of RNA solution from the 14 μl-
eluate from RNA isolation of 200 μl serum sample was
used as input into the reverse transcription. Input RNA
was reverse transcribed using the TaqMan miRNA Re-
verse Transcription kit and miRNA-specific stem-loop
primers (Life Technologies, Madrid, Spain). The reaction
was conducted in a GeneAmp PCR System 9700 (Life
Technologies) at 16°C for 30 min, 42°C for 30 min and
85°C for 5 min. A preamplification step was performed
at 95°C for 10 min, 20 cycles of 95°C for 15 seconds,
and 60°C for 4 min. Real-time PCR was carried out on aRoche LightCycler 480 (Roche Applied Science, Penzberg,
Germany) at 95°C for 10 min, followed by 40 cycles of 95°C
for 15 s and 60°C for 1 min using the TaqMan micro-
RNA assay together with TaqMan Universal PCR Mas-
ter Mix, No AmpErase UNG (Applied Biosystems, San
Francisco, CA, USA). Data were normalized to the
mean of spiked-in miRNA Cel-miR-39. The Ct mean
values of the spiked-in miRNA Cel-miR-39 in the
groups T1 and T2 were 16.10 and 16.20 respectively.
BestKeeper software was used to evaluate whether this
miRNA was a good reference miRNA [19]. After
uploading each Ct value in the Excel spreadsheet, the
BestKeeper standard deviation (SD) value was lower
than 1, thus considering this miRNA as a good stable
housekeeping gene for our experimental conditions.
The expression levels of miRNAs were calculated using
the 2-ΔΔCt method.
Statistical analysis
All data were expressed as mean ± SD. Statistical analyses
were performed with SSPS 17.0 (SPSS Inc., Chicago, IL,
USA). Following normality and equality of variance tests,
clinical characteristics were compared using paired Stu-
dent’s t test or alternatively by a nonparametric test
(Mann-Whitney rank sum test). Paired samples within the
same subjects were compared by Wilcoxon signed-rank
test. Differences among groups of treatment were ana-
lyzed by repeated measures ANOVA. Correlations were
assessed by Spearman’s rank correlation. Differences were
considered significant at P <0.05.
Receiver operating characteristic (ROC) curve ana-
lyses, plotting the true positive rate (sensitivity) vs. the
false positive rate (1-specificity) at various threshold set-
tings were performed for serum miRNAs, and the areas
under the curve (AUCs) were calculated with SPSS.
ROC analysis for miRNA-combined, arithmetic mean of
level expression was calculated from two miRNAs se-
lected with the highest efficiency values. P values <0.05
were considered statistically significant.
Results
Clinical response to anti-TNFα/DMARDs combination
therapy
Within the cohort, 83 patients were female (87%) and 12
male (13%) with median disease duration of 9 (4 to 14)
years. At the start of the anti-TNFα/DMARDs combin-
ation therapy all subjects showed high disease activity,
reflected by a mean DAS28 of 5.67 (5.29 to 6.11) despite
a median number of 2.35 DMARDS agents used con-
comitantly (range 1 to 3). All patients took non-steroidal
anti-inflammatory drugs (NSAIDs) daily and 65% of
them received steroid treatment (range 5 to 15 mg/d
prednisone). Methotrexate alone or in combination was
administered in 68.4% of subjects.
Castro-Villegas et al. Arthritis Research & Therapy  (2015) 17:49 Page 5 of 15According to DAS28 response criteria, 90% of patients
were responders to anti-TNFα/DMARDs combination
therapy. At 6 months of therapy most of the clinical pa-
rameters evaluated (including TJC, SJC, SDAI, and HAQ)
improved significantly. All three biological agents had a fa-
vorable influence on the evolution of those parameters
(Tables S1 and S2 in Additional file 1). Several auto-
immune and serological parameters (such as RF, PCR,
ESR, IL6, IL17, and TNFα) were further significantly re-
duced when patients were classified in responder vs. non-
responder (Table 2). Thus, we chose the time after starting
therapy to assess serum miRNAs changes.
Differentially expressed miRNAs in the serum of RA
patients before and after anti-TNFα/DMARDs combination
therapy
To evaluate the expression of serum miRNAs before and
after anti-TNFα/DMARDs combination therapy, we pro-
filed miRNA spectra from pools of RNA purified from
10 RA serum samples before treatment and 10 RA
serum samples after treatment (exploratory cohort). We
tested 84 miRNAs during this analysis process. In this
profile, the expression levels of 75 miRNAs were foundTable 2 Changes operated on clinical and laboratory parame
non-responder RA patients






TJC 15.9 ± 4.8 5.1 ± 2.2
SJC 11.7 ± 3.9 2.9 ± 1.8
DAS28 5.8 ± 0.6 3.3 ± 0.7
SDAI 36.3 ± 11.4 2.9 ± 6.8
HAQ 2.1 ± 0.3 1 ± 0.4
Serological assessments
ESR (mm/h) 56.4 ± 17.2 27.9 ± 18.5
CRP (mg/L) 3.9 ± 2.1 1.5 ± 1.2
RF (U/L) 155.2 ± 288.3 85.4 ± 241
IL-6 (pg/mL) 9.4 ± 46.7 1.4 ± 6.8
TNF (pg/mL) 14.9 ± 28.8 5.7 ± 6.1
sTNFRII (pg/mL) 1.5 ± 0.9 1.5 ± 0.7
MCP-1 (pg/mL) 1174.8 ± 1615.4 1216.4 ± 1655.4
VEGF (pg/mL) 1107.7 ± 1360.9 830.3 ± 570.1
IL23 (pg/mL) 115 ± 235.5 76.8 ± 132.9
IL22 (pg/mL) 46.3 ± 112 17.2 ± 29.2
IL17 (pg/mL) 4.8 ± 8.5 2.1 ± 2.1
IL4 (pg/mL) 22.8 ± 17.6 14.9 ± 16.2
TNFα, tumor necrosis factor alpha; DMARDS, disease-modifying antirheumatic drugs
SJC, swollen joint count; DAS28, disease activity score; SDAI, simplified disease activity
CRP, C-reactive protein; RF, rheumatoid factor; IL-6, interleukin 6; TNF, tumor necrosis f
chemoattractant protein 1; VEGF, vascular endothelial growth factor; IL-23, interleukinincreased, while 9 miRNAs decreased after treatment
(Figure 1A).
A detailed analysis of the altered miRNAs in response
to anti-TNFα/DMARDs combination treatment, by
using the Ingenuity Pathway Analysis (IPA), showed that
a large number of them had target mRNAs involved in
immune and inflammatory response, cardiovascular sys-
tem development and function, or connective tissue and
musculoskeletal system. Interestingly, among all the po-
tential effects, we found a cluster of miRNAs (which in-
creased after therapy) that may result in a significant
impact on the reduction of the maturation of cells, espe-
cially on chondrocytes. Also our results seem to indicate
that G1 phase transition may be inhibited (Figure 1B).
Validation of the differentially expressed miRNAs
To validate the PCR array data, five miRNAs differen-
tially expressed, showing at least 2-fold change between
the two conditions, were selected (hsa-miR-125b, hsa-
miR-23a-3p, hsa-miR-21-5p, hsa-miR-126-3p and hsa-
miR-146a-5p). A second group of five miRNAs under
2-fold change but involved in processes such as inflam-
mation, cardiovascular and autoimmune diseases, andters after anti-TNFα/DMARDs treatment in responder and






0.000 15.6 ± 5.1 8.5 ± 2.9 0.005
0.000 11.6 ± 4.9 5.1 ± 2.7 0.005
0.000 5.5 ± 0.7 4.3 ± 0.6 0.005
0.000 39.2 ± 11.8 5.7 ± 12.1 0.005
0.000 2.1 ± 0.3 1 ± 0.3 0.008
0.000 51.4 ± 11.9 37.6 ± 19.3 ns
0.000 2.2 ± 0.8 2.5 ± 0.9 ns
0.000 61.2 ± 84.3 20.8 ± 39.9 0.027
0.000 2.1 ± 5.6 0 ns
0.038 4.1 ± 4.5 4.7 ± 5.1 ns
ns 1.3 ± 0.4 1.5 ± 0.7 ns
ns 740 ± 504.6 678.6 ± 221.8 ns
ns 796.7 ± 462.7 1077.9 ± 711.6 ns
ns 41.2 ± 30.5 223.5 ± 424.8 ns
ns 8.4 ± 8.1 104.9 ± 193.3 ns
0.024 11.9 ± 19.1 1.4 ± 1.4 ns
ns 4.2 ± 6 12.8 ± 18.2 ns
; RA, rheumatoid arthritis; T1 baseline; T2 at 6 months; TJC, tender joint count;
index; HAQ, health assessment questionnaire; ESR, erythrocyte sedimentation rate;
actor; sTNFRII, soluble tumor necrosis factor receptor type II; MCP-1, monocyte







chondrocyte cell lines 3,35E-11 -2,236
Maturation of cells 1,60E-03 -2,219
G1 phase 9,38E-05 -2,202
G1/S phasetransition 7,25E-04 -2,202
B
Figure 1 Plasma miRNA profiling using miRNA array. (A) To identify the changes that occurred in the expression levels of miRNAs in serum
from patients treated with anti-TNFα/DMARDs combination therapy, Human Serum & Plasma miRNA PCR array (Qiagen) was performed. In this
profile, the expression levels of 75 miRNAs were found increased, while 9 miRNAs decreased after treatment. (B) All the miRNAs modified after
anti-TNFα/DMARDs treatment together with the observed fold change were analyzed using the IPA software in order to find interrelationships
and potential impact on specific pathways. Among all the targets, the most significant findings (P value <0.01) indicated that maturation of cells
and transition to G1 phase were inhibited. DMARDs, disease-modifying antirheumatic drugs; IPA, Ingenuity Pathway Analysis; miRNAs, microRNAs;
TNFα, tumor necrosis factor alpha.
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miR-124a-3p, hsa-miR-155-5p, hsa-miR-223-3p). The
changes that occurred in the expression of the selected
miRNAs were evaluated in all the patients included in
the study. In total population, six of the ten miRNAs
clearly distinguished RA serum samples after anti-
TNFα/DMARDs combination therapy with high confi-
dence level (P <0.05): (hsa-miR-125b, hsa-miR-126-3p,
hsa-miR146a-5p, hsa-miR-16-5p, hsa-miR-23-3p, and
hsa-miR-223-3p) all of them being increased after treat-
ment (Figure 2A; Tables S3 and S4 in Additional file 1).
These differences were found even more relevant when
patients were divided in responders and non-responders,
so that while miRNA expression levels strongly increased
in responders, they did not change in non-responder pa-
tients after anti-TNFα/DMARDs combination therapyFigure 2 Relative miRNA levels at start (T1) and after six months of ant
(n = 85). To validate the PCR array data, ten miRNAs differentially expressed w
3p, hsa-miR-146a-5p, hsa-let-7a-5p, hsa-miR-16-5p, hsa-miR-124a-3p, hsa-miR-
are shown. Boxes indicate the interval between the 25th and 75th percentiles
interval of data within 1.5 × interquartile ranges (IQR). Closed circles indicate d
of miRNA levels between responders and non-responders groups for the six m
*P <0.05. DMARDs, disease-modifying antirheumatic drugs; miRNAs, microRNA(Figure 2B, and Figure S4 in Additional file 2). Moreover,
in responders, a parallel change was observed in the ex-
pression levels of autoimmune parameters such as the RF
and of some cytokines such as TNFα, IL-6 or IL-17, which
were found significantly reduced after treatment (Table 2).
Regulation network of differentially expressed serum
miRNAs in the inflammatory pathways and processes of
rheumatoid arthritis
It is widely accepted that miRNAs can influence gene
expression by causing translational repression or mRNA
degradation. This dysregulation can alter several down-
stream pathways and manifest effects. By using the IPA
software, we further investigated the potential gene tar-
gets for the six validated miRNAs and analyzed their
participation in the different canonical pathways (Figure 3).i-TNFα/DMARDs combination therapy (T2) in the validation cohort
ere selected (hsa-miR-125b, hsa-miR-23a-3p, hsa-miR-21-5p, hsa-miR-126-
155-5p, and hsa-miR-223). (A) Relative expression levels of each miRNA
and horizontal bars inside boxes indicate median. Whiskers indicate the
ata points outside 1.5 x IQR. *P <0.05. (B) Comparison of relative change
iRNAs found significantly altered after therapy in the validation cohort.
s; TNFα, tumor necrosis factor alpha.
Figure 3 Participation of the six validated miRNAs in the different canonical pathways. Ingenuity Pathway Analysis (IPA) uncovered the
main enriched biological pathways on which that miRNAs are involved. The analysis included only the pathways with average IPA score >2
(indicated as -log (P value)). miRNAs, microRNAs.
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score >2 (−log (P value)) were included, revealed that the
most probable genes modified by these miRNA corres-
pond to pathways directly related to RA (that is, the role
of macrophages, fibroblasts and endothelial cells in RA,
the role of osteoblasts, osteoclasts and chondrocytes in
RA, and the role of IL-17A in RA). Pathways related to
STAT-3 or IL-6 signaling (both of them crucial for the in-
duction and maintenance of the inflammatory status
present in RA patients), were also identified.
To better understand the significance of the results, we
investigated the potential impact of the verified miRNAs
directly on the RA-related pathways. A deeper analysis of
the miRNA targets demonstrated that RA-related canon-
ical pathways may be regulated at different levels (grey-
filled symbols of genes in Figure S1 in Additional file 3:
Figure S2 in Additional file 4; and Figure S3 in Additional
file 5). It is also interesting to note that in this study we
found that several genes were the targets of more than
one of the verified miRNAs (Table 3). For example, the
gene that codifies for conserved helix-loop-helix ubiqui-
tous kinase (CHUK) may be potentially regulated by four
out of the six miRNAs. Other genes directly related to RA
are multiple targets for these miRNAs, such as IL6receptor alpha (IL6R) and beta (IL6ST) chains, fibroblast
growth factor 2 (FGF2), and the bone morphogenetic pro-
tein receptor type II (BMPRII). Interestingly, a number of
both miRNA and mRNA targets uncovered in that ana-
lysis were found complementary altered after anti-TNFα/
DMARDs combination therapy in our patient’s cohort
(that is IL-6 or IL-17 serum levels).Changes in serum miRNAs correlate with changes in
clinical variables in RA patients
To assess the possibility of serum miRNAs as biomarkers
of RA and of response to therapy, we investigated the cor-
relation of validated miRNAs with clinical and inflamma-
tory variables. The changes observed in three miRNAs
(hsa-miR-146a-5p, hsa-miR-223-3p and hsa-miR-16-5p)
significantly correlated with the changes observed in clin-
ical parameters (that is, DAS28), and five of them at least
with changes in inflammatory parameters such as CRP
or ESR (hsa-miR-146a-5p, hsa-miR-223-3p,hsa-miR-16-
5p, hsa- miR-126-3p and hsa-miR-23-3p) (Figure 4). A
direct and significant relationship was also demonstrated
among all the miRNAs (data not shown). In parallel, as
described above, IPA analysis showed specific networks
Table 3 Potential genes directly related to rheumatoid arthritis that constitute direct targets of the validated miRNAs
miR-146 miR-223 miR-125b miR-126 miR-23 miR-16 Entrez Gene NaME
Role of macrophages, fibroblasts and endothelial cells in rheumatoid arthritis
- - APC APC - - - - - - Adenomatous polyposis coli
- - - - - - - - CCND1 CCND1 Cyclin D1
CHUK CHUK - - - - CHUK CHUK Conserved helix-loop-helix ubiquitous kinase
- - FGF2 - - - - FGF2 FGF2 Fibroblast growth factor 2 (basic)
- - FZD4 - - - - FZD4 FZD4 Frizzled class receptor 4
IL36B - - - - - - - - IL36B Interleukin 36, beta
IL-36RN - - - - - - - - IL36RN Interleukin 36 receptor antagonist
- - - - IL6R - - IL6R - - Interleukin 6 receptor
- - IL6ST - - - - IL6ST - - Interleukin 6 signal transducer
IRAK2 - - - - - - - - IRAK2 Interleukin-1 receptor-associated kinase 2
- - - - - - LRP6 - - LRP6 Low-density lipoprotein receptor-related protein 6
- - PIK3C2A - - - - PI3KC2A - - Phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha
- - - - PI3KCD PI3KCD - - - - Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
PRKCE PRKCE - - - - PRKCE - - Protein kinase C, epsilon
Role of osteoblasts, osteoclasts and chondrocytes in rheumatoid arthritis
miR-146 miR-223 miR-125b miR-126 miR-23 miR-16 Entrez Gene NaME
- - - - - - - - ADAMTS5 ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif, 5
- - APC APC - - - - - - Adenomatosus polyposis coli
- - - - BCL2 - - BCL2 BCL2 B-cell LL/lymphoma 2
- - - - BMPR2 - - BMPR2 - - Bone morphogenetic protein receptor, type II
(serine/threonine kinase)
CHUK CHUK - - - - CHUK CHUK Conserved helix-loop-helix ubiquitous kinase
- - FOXO1 - - - - - - FOXO1 Forkhead box 01
- - FZD4 - - - - FZD4 FZD4 Frizzled class receptor 4
IL1F10 - - IL1F10 - - - - - - Interleukin 1 family, member 10 (theta)
IL36B - - - - - - - - IL36B Interleukin 36, beta
IL36RN - - - - - - - - IL36RN Interleukin 36 receptor antagonist
- - - - - - LRP6 - - LRP6 Low-density lipoprotein receptor-related protein 6
- - PIK3C2A - - - - PI3KC2A - - Phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha
- - - - PI3KCD PI3KCD - - - - Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
XIAP XIAP - - - - - - - - X-linked inhibitor of apoptosis
Role of IL-17A in arthritis
miR-146 miR-223 miR-125b miR-126 miR-23 miR-16 Entrez Gene NaME
PIK3CD - - - - PIK3CD - - - - Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Only those genes regulated by at least two of the validated miRNAs are included in the table. miRNA, microRNA; IL-17A, interleukin 17A.
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associated to RA disease.
Serum miRNAs hsa-miR-23a-3p and hsa-miR-223-3p as
predictors of therapy response in RA patients
As a general feature, we found that the better the status
of the patient before the treatment (in terms of clinical
and serological parameters) the lowest changes in DASand levels of miRNAs were found after anti-TNFα/
DMARDs combination therapy. In particular, elevated
levels of miRNAs before starting the therapy were indi-
cative of no response (Figure 5A).
That data were further supported by ROC analyses,
which showed that hsa-miR-23-3p and hsa-miR-223-3p
levels at T1, with a cutoff value of 6.9 and 11.2 (relative
expression at T1) respectively, were predictors of non-
Figure 4 Changes in serum miRNAs correlate with changes in clinical variables in RA patients. Changes after anti-TNFα/DMARDs combination
therapy (T1-T2) of various miRNAs significantly correlated with the changes in DAS28 (A-C), in CRP (D-E) and in ESR (F). r values of Spearman’s
rank correlation and P values of their null hypothesis are shown. CRP, C-reactive protein; DAS28, disease activity score; DMARDs, disease-modifying
antirheumatic drugs; ESR, erythrocyte sedimentation rate; miRNAs, microRNAs; RA, rheumatoid arthritis; T1, baseline; T2, at 6 months; TNFα, tumor
necrosis factor alpha.
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(Figure 5B-C) with a sensitivity of 62.5% and 57.1%, and
a specificity of 86.4% and 90.2% respectively. The ana-
lysis of changes in relative expression of miRNAs after
treatment further showed a downregulation instead ofFigure 5 Evaluation of candidate miRNAs as predictors of response to t
plasma of RA patients (n = 95) before starting the anti-TNFα/DMARDs combin
under the curve (AUC) was calculated after plotting the receiver operating ch
and miR-223-3p (right panel), which showed the highest values for AUC; belo
described in Material and methods. (C) Sensitivity and specificity of each miRN
disease-modifying antirheumatic drugs; miRNAs, microRNAs; RA, rheumatoidupregulation in RA patients non-responders, while in re-
sponders, a significant increase in three of the miRNAs
validated was demonstrated (Figure 6A).
To evaluate their relevance as biomarkers in response to
anti-TNFα/DMARDs combination therapy, we conductedherapy. (A) Relative expression levels of the six miRNAs validated in
ation therapy (T1). Data are shown as mean ± standard deviation. Area
aracteristic (ROC) curve. (B) ROC curve analyses of miR-23a-3p (left panel)
w is shown the combined panel for the two miRNAs that performed as
A test. Cutoff value with higher specificity was selected. DMARDs,
arthritis; T1, baseline; TNFα, tumor necrosis factor alpha.
Figure 6 Evaluation of candidate miRNAs as potential biomarkers of response to anti-TNFα/DMARDs combination therapy. (A) Changes in
relative expression levels of the six miRNAs validated in plasma of RA patients (n = 95) before and after anti-TNFα/DMARDs combination therapy (T1-T2).
Data are shown as mean ± standard deviation. Area under the curve (AUC) was calculated after plotting the receiver operating characteristic (ROC)
curve. (B) ROC curve analyses of miR-23a-3p (left panel) and miR-223-3p (right panel), which showed the highest values for AUC; below is shown the
combined panel for the two miRNAs performed as described in Material and methods. (C) Sensitivity and specificity of each miRNA test. Cutoff value
with higher specificity was selected. DMARDs, disease-modifying antirheumatic drugs; miRNAs, microRNAs; RA, rheumatoid arthritis; T1, baseline; T2, at
6 months; TNFα, tumor necrosis factor alpha.
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highest AUC for miR-23 and miR-223. Changed relative
expression between T1 and T2 for miR-23, at a cutoff
value of 0.83, demonstrated a sensitivity of 62.5% and
a specificity of 77.6%. At a cutoff value of 3.03 for
miR-223, the values were 57.1% and 84.3% respectively
(Figure 6A-C).
To improve accuracy of the analysis, we performed the
combination of ROC curve analyses of miR-23, and
miR-223. The ratio of combination for these miRNAs at
T1 demonstrated an increase in both the sensitivity
(62.5%) and specificity (91.5%) in relation to those given
by each miRNA alone (Figure 6B-C). The ratio of com-
bination for the change of these miRNAs (T1-T2) also
yielded the highest AUC value of 0.88 and at the optimal
cutoff value of 1.5, the sensitivity and specificity were
62.5% and 84.7%, (Figure 6B-C).
Taken together, these results suggest that serum hsa-
miR-23a-3p and hsa-miR-223-3p can act both as pre-
dictors of therapy response and biomarkers of response
to anti-TNFα/DMARDs combination therapy with high
specificity.Discussion
MicroRNAs are emerging as potential targets for new
therapeutic strategies of autoimmune disorders. In the
present study, data on miRNA serum levels of RA pa-
tients before and after anti-TNFα/DMARDs combin-
ation therapy, and their close relationship with the
improvement of the disease, suggest their potential use
as novel biomarkers for monitoring therapy outcome.
Almost all of the RA patients showed complete clinical
response to anti-TNFα/DMARDs combination therapy,
not only in disease activity (swollen joints, painful pain
scales, DAS28, and so on), but also in physical function,
quality of life, fatigue, and sleep (HAQ). These results
validate previous studies [20,21].
Most of the miRNAs evaluated - in the setting of our
PCR array - were found increased in response to treat-
ment. Since miRNAs generally act as negative regulators
of their target proteins, the increase in the levels of miR-
NAs could imply a reduction in the expression of all
their target proteins, which were altered in their expression
in RA patients before the biological therapy. In this regard,
the functional classification allowed us to demonstrate
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target molecules/proteins/transcription factors involved
in inflammation and autoimmunity processes, activa-
tion of T and B cells, musculoskeletal dysfunction or
cardiovascular disease. Therefore, the increase in the
levels of those miRNAs after anti-TNFα/DMARDs
combination therapy might be associated to a reduction
in the inflammatory profile and the improvement of the
overall disease status of patients. In support for this hy-
pothesis, we further found a significant reduction in the
serum levels of inflammatory and autoimmunity markers.
The proteolytic degradation of extracellular matrix
(ECM) molecules in articular cartilage in the joint is a
crucial catabolic event in RA [22]. Synoviocytes and syn-
ovial macrophages produce inflammatory mediators in-
cluding prostaglandins, reactive oxygen species and
proinflammatory cytokines (such as IL-1ß, IL-6 and
TNFα) that stimulate articular chondrocytes to produce
matrix-degrading enzymes such as matrix metelloprotei-
nases, leading to the destruction and degeneration of the
cartilage ECM [23]. Thus, a putative effect on the reduc-
tion of chondrocyte maturation (as identified in the clus-
ter of miRNAs found increased after therapy), might
have beneficial effects on the prevention of the articular
damage in RA patients.
The miRNAs validated by RT-PCR in our cohort of
patients (miR146a-5p, miR-16-5p, miR-23-3p, miR-
125b-5p, miR223-3p; miR126-3p) have been previously
reported to act as relevant regulators of immune cells
development, playing crucial roles in the inflammatory
response, and acting as key players in the pathogenesis
of various chronic and autoimmune disorders, includ-
ing RA itself [24].
It is also interesting to note that in this study we found
that several genes were the targets of more than one of
the verified miRNAs (Table 3). For example, the gene
that codifies for CHUK may be potentially regulated by
four out of the six miRNAs. CHUK (conserved helix-
loop-helix ubiquitous kinase, also known as inhibitor of
nuclear factor kappa-B kinase subunit alpha (IKK-α), or
IKK1) is a protein kinase that mediates IkappaB phos-
phorylation and nuclear factor kappa B (NFkB) activa-
tion [25]. Almost all of the proinflammatory factors
involved in the pathogenesis and progression of RA (that
is, IL-6 or TNFα) are regulated by the transcription fac-
tor NFkB. Thus, drugs that modulate the activation and
function of CHUK are likely to have therapeutic value in
inflammatory disease such as RA.
Other genes directly related to RA were also found to
be multiple targets for these miRNAs, including IL6 re-
ceptor alpha (IL6R) and beta (IL6ST) chains, FGF-2, a
number of intracellular molecules, and the BMPR2.
Current studies showed that, in addition to their role
in enhancing autoantibody production, IL-6 promotessynovial tissue inflammation and osteoclastogenesis, lead-
ing to the severe synovitis with pannus formation and the
progressive cartilage and bone destruction in multiple
joints found in RA [26]. Moreover, IL-6 is an important
contributor to the development of cardiovascular disease
(CVD) in RA patients [27]. In our cohort, IL-6 receptors
alpha and beta were found to be putative targets for three
of the six validated miRNAs (hsa-miR-23-3p, hsa-miR-
125b-5p, and hsa-miR223-3p). In parallel, plasma analysis
showed that anti-TNF drugs promoted a significant reduc-
tion on IL-6 levels, thus suggesting a role for those miRNAs
in the regulation of IL-6 production.
A direct target for three of the validated miRNAs
found altered in RA patients after anti-TNF/DMARDs
therapy was the FGF-2. In the synovial fluid FGF2 plays
a role in the final step of osteoclastic bone resorption in
RA joint destruction that is preceded by recruitment
and differentiation of osteoclasts by other factors. Thus,
endogenous FGF2 might participate in the pathogenesis
of that bone resorptive disease through its direct action
on osteoclasts [28].
From a molecular point of view, the severity and prog-
nosis of RA are dependent on the balance between in-
flammatory or destructive pathways and homeostatic or
repair pathways [29]. In that way, class I phosphoinosi-
tide 3 kinase (PI3K) δ is a promising therapeutic target
for RA. PI3Kδ is highly expressed in RA synovium, espe-
cially in the synovial lining. Its expression is selectively
induced by the inflammatory cytokines TNF and IL-1. It
has been demonstrated that PI3Kδ is a major regulator
of platelet-derived growth factor (PDGF)-mediated fibro-
blast growth and survival via Akt [30]. Thus, targeting
PI3Kδ in RA could modulate synoviocyte function via
anti-inflammatory and disease-altering mechanisms. Fur-
thermore, the family of PI3Ks plays an important role in
the pathogenesis of CVD by modulating several essential
biologic processes, such as metabolism, vascular homeo-
stasis and thrombogenicity [31]. In fact, various observa-
tions indicate that pharmacological inhibition of PI3Ks
may be a new therapeutic strategy for preventing cardio-
vascular complications in this autoimmune disease.
Increasing evidence suggests a role for bone morpho-
genetic protein (BMP) signaling in joint homeostasis and
disease. BMP signaling, induced through the binding of
a dimeric BMP ligand to type I and type II BMP recep-
tors, has a key role in the pathogenesis of RA [32].
Moreover, it has been shown that BMP expression can
be regulated by anti-TNFα drugs [33], thus supporting a
relevant role for the miRNAs involved in the response to
treatment and having that receptor as a target.
Consistent with our results, a recent study has shown
the association of two of the miRNAs found significantly
increased in response to anti-TNFα/DMARDs combin-
ation therapy in our study (hsa-miR-223-3p, and hsa-
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agnosed [34]. Furthermore, three trials in 2008 indicated
the existence of altered expression of some of those
miRNAs (hsa-miR-16-3p, hsa-miR-132, hsa-miR-146a-
5p and hsa-miR-155-3p) in leukocytes of arthritic pa-
tients [35]. A more recent study showed that decreased
expression of hsa-miR-146a and hsa-miR-155-3p con-
tributes to an abnormal Treg phenotype in patients with
RA [36]. In support for that previously reported data,
correlation studies in our cohort demonstrated, first, the
existence of a significant relationship among all the vali-
dated miRNAs. Moreover, all of them have putative tar-
gets directly associated to RA disease and involved in
the response to anti-TNFα drugs.
Second, we found a negative correlation between the
changes in the expression levels of almost all the vali-
dated miRNAs and the changes occurred in various clin-
ical and inflammatory parameters. Furthermore, ROC
analyses demonstrated that two of these six miRNAs
(hsa-miR-23-3p and hsa-miR-223-3p) can act in RA pa-
tients as both predictors of therapy response (indicating
those patients who would not benefit from anti-TNFα/
DMARDs combination therapy), and as biomarkers of
response to anti-TNFα/DMARDs combination therapy
(so that their levels would be indicative of treatment effi-
cacy and also of the degree of response).
Our data contrast with a recent study performed in
patients with psoriasis treated with the TNFα-inhibitor
etanercept [37]. In that cohort of patients, etanercept
significantly downregulated serum levels of hsa-miR-
223-3p and hsa-miR-126-5p among others. In addition,
those miRNAs were not related to disease severity in
psoriasis. Those results suggest a distinctive involvement
of similar miRNAs in pathways affected by anti-TNFα/
DMARDs combination therapy depending on the in-
flammatory disease concerned.Conclusions
Altogether, our data suggest that differentially expressed
miRNAs in the serum of RA patients before and after
anti-TNFα/DMARDs combination therapy have poten-
tial to serve as novel biomarkers for predicting and
monitoring therapy outcome.
Since we did not perform a complete plasma human
microarray analysis, we cannot exclude the complemen-
tary role of other circulating miRNAs in the response to
treatment, and because of the clinical heterogeneity of RA
patients, our data must be confirmed in larger studies.
Moreover, specific studies on the mechanisms underlying
the altered expression of those miRNAs after anti-TNFα/
DMARDs combination therapy, as well as the identifica-
tion of the mechanism and cellular sources of those extra-
cellular miRNAs are still required.Additional files
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